U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Adenocarcinoma of lung, response to tyrosine kinase inhibitor in, somatic

MedGen UID:
342039
•Concept ID:
C1851577
•
Neoplastic Process
Synonym: ADENOCARCINOMA OF LUNG, RESPONSE TO TYROSINE KINASE INHIBITOR IN, SOMATIC
 
OMIM®: 131550

Professional guidelines

PubMed

Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy.
Kobayashi Y, Mitsudomi T
Cancer Sci 2016 Sep;107(9):1179-86. Epub 2016 Aug 9 doi: 10.1111/cas.12996. PMID: 27323238Free PMC Article
Management and future directions in non-small cell lung cancer with known activating mutations.
Gerber DE, Gandhi L, Costa DB
Am Soc Clin Oncol Educ Book 2014:e353-65. doi: 10.14694/EdBook_AM.2014.34.e353. PMID: 24857124
Gefitinib for the treatment of non-small-cell lung cancer.
Hida T, Ogawa S, Park JC, Park JY, Shimizu J, Horio Y, Yoshida K
Expert Rev Anticancer Ther 2009 Jan;9(1):17-35. doi: 10.1586/14737140.9.1.17. PMID: 19105704

Recent clinical studies

Etiology

Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR-Mutant Lung Adenocarcinoma.
Vokes NI, Chambers E, Nguyen T, Coolidge A, Lydon CA, Le X, Sholl L, Heymach JV, Nishino M, Van Allen EM, Jänne PA
J Thorac Oncol 2022 Jun;17(6):779-792. Epub 2022 Mar 21 doi: 10.1016/j.jtho.2022.02.011. PMID: 35331964Free PMC Article
SBRT for oligoprogressive oncogene addicted NSCLC.
Basler L, Kroeze SG, Guckenberger M
Lung Cancer 2017 Apr;106:50-57. Epub 2017 Feb 6 doi: 10.1016/j.lungcan.2017.02.007. PMID: 28285694
ERBB2-Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies.
Chuang JC, Stehr H, Liang Y, Das M, Huang J, Diehn M, Wakelee HA, Neal JW
J Thorac Oncol 2017 May;12(5):833-842. Epub 2017 Feb 4 doi: 10.1016/j.jtho.2017.01.023. PMID: 28167203Free PMC Article
EGFR assays in lung cancer.
Dacic S
Adv Anat Pathol 2008 Jul;15(4):241-7. doi: 10.1097/PAP.0b013e31817bf5a9. PMID: 18580100
Factors predicting response to EGFR tyrosine kinase inhibitors.
Engelman JA, Jänne PA
Semin Respir Crit Care Med 2005 Jun;26(3):314-22. doi: 10.1055/s-2005-871990. PMID: 16052433

Diagnosis

Modeling Clinical Responses to Targeted Therapies by Patient-Derived Organoids of Advanced Lung Adenocarcinoma.
Kim SY, Kim SM, Lim S, Lee JY, Choi SJ, Yang SD, Yun MR, Kim CG, Gu SR, Park C, Park AY, Lim SM, Heo SG, Kim H, Cho BC
Clin Cancer Res 2021 Aug 1;27(15):4397-4409. Epub 2021 Jun 3 doi: 10.1158/1078-0432.CCR-20-5026. PMID: 34083237Free PMC Article
SBRT for oligoprogressive oncogene addicted NSCLC.
Basler L, Kroeze SG, Guckenberger M
Lung Cancer 2017 Apr;106:50-57. Epub 2017 Feb 6 doi: 10.1016/j.lungcan.2017.02.007. PMID: 28285694
Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy.
Kobayashi Y, Mitsudomi T
Cancer Sci 2016 Sep;107(9):1179-86. Epub 2016 Aug 9 doi: 10.1111/cas.12996. PMID: 27323238Free PMC Article
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M
Science 2004 Jun 4;304(5676):1497-500. Epub 2004 Apr 29 doi: 10.1126/science.1099314. PMID: 15118125
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA
N Engl J Med 2004 May 20;350(21):2129-39. Epub 2004 Apr 29 doi: 10.1056/NEJMoa040938. PMID: 15118073

Therapy

Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR-Mutant Lung Adenocarcinoma.
Vokes NI, Chambers E, Nguyen T, Coolidge A, Lydon CA, Le X, Sholl L, Heymach JV, Nishino M, Van Allen EM, Jänne PA
J Thorac Oncol 2022 Jun;17(6):779-792. Epub 2022 Mar 21 doi: 10.1016/j.jtho.2022.02.011. PMID: 35331964Free PMC Article
RET fusions in solid tumors.
Li AY, McCusker MG, Russo A, Scilla KA, Gittens A, Arensmeyer K, Mehra R, Adamo V, Rolfo C
Cancer Treat Rev 2019 Dec;81:101911. Epub 2019 Oct 30 doi: 10.1016/j.ctrv.2019.101911. PMID: 31715421
Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy.
Kobayashi Y, Mitsudomi T
Cancer Sci 2016 Sep;107(9):1179-86. Epub 2016 Aug 9 doi: 10.1111/cas.12996. PMID: 27323238Free PMC Article
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M
Science 2004 Jun 4;304(5676):1497-500. Epub 2004 Apr 29 doi: 10.1126/science.1099314. PMID: 15118125
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA
N Engl J Med 2004 May 20;350(21):2129-39. Epub 2004 Apr 29 doi: 10.1056/NEJMoa040938. PMID: 15118073

Prognosis

Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR-Mutant Lung Adenocarcinoma.
Vokes NI, Chambers E, Nguyen T, Coolidge A, Lydon CA, Le X, Sholl L, Heymach JV, Nishino M, Van Allen EM, Jänne PA
J Thorac Oncol 2022 Jun;17(6):779-792. Epub 2022 Mar 21 doi: 10.1016/j.jtho.2022.02.011. PMID: 35331964Free PMC Article
Modeling Clinical Responses to Targeted Therapies by Patient-Derived Organoids of Advanced Lung Adenocarcinoma.
Kim SY, Kim SM, Lim S, Lee JY, Choi SJ, Yang SD, Yun MR, Kim CG, Gu SR, Park C, Park AY, Lim SM, Heo SG, Kim H, Cho BC
Clin Cancer Res 2021 Aug 1;27(15):4397-4409. Epub 2021 Jun 3 doi: 10.1158/1078-0432.CCR-20-5026. PMID: 34083237Free PMC Article
SBRT for oligoprogressive oncogene addicted NSCLC.
Basler L, Kroeze SG, Guckenberger M
Lung Cancer 2017 Apr;106:50-57. Epub 2017 Feb 6 doi: 10.1016/j.lungcan.2017.02.007. PMID: 28285694
Epidermal growth factor receptor mutations in lung adenocarcinoma.
Siegelin MD, Borczuk AC
Lab Invest 2014 Feb;94(2):129-37. Epub 2013 Dec 30 doi: 10.1038/labinvest.2013.147. PMID: 24378644
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M
Science 2004 Jun 4;304(5676):1497-500. Epub 2004 Apr 29 doi: 10.1126/science.1099314. PMID: 15118125

Clinical prediction guides

Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR-Mutant Lung Adenocarcinoma.
Vokes NI, Chambers E, Nguyen T, Coolidge A, Lydon CA, Le X, Sholl L, Heymach JV, Nishino M, Van Allen EM, Jänne PA
J Thorac Oncol 2022 Jun;17(6):779-792. Epub 2022 Mar 21 doi: 10.1016/j.jtho.2022.02.011. PMID: 35331964Free PMC Article
Modeling Clinical Responses to Targeted Therapies by Patient-Derived Organoids of Advanced Lung Adenocarcinoma.
Kim SY, Kim SM, Lim S, Lee JY, Choi SJ, Yang SD, Yun MR, Kim CG, Gu SR, Park C, Park AY, Lim SM, Heo SG, Kim H, Cho BC
Clin Cancer Res 2021 Aug 1;27(15):4397-4409. Epub 2021 Jun 3 doi: 10.1158/1078-0432.CCR-20-5026. PMID: 34083237Free PMC Article
Management and future directions in non-small cell lung cancer with known activating mutations.
Gerber DE, Gandhi L, Costa DB
Am Soc Clin Oncol Educ Book 2014:e353-65. doi: 10.14694/EdBook_AM.2014.34.e353. PMID: 24857124
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M
Science 2004 Jun 4;304(5676):1497-500. Epub 2004 Apr 29 doi: 10.1126/science.1099314. PMID: 15118125
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA
N Engl J Med 2004 May 20;350(21):2129-39. Epub 2004 Apr 29 doi: 10.1056/NEJMoa040938. PMID: 15118073

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Consumer resources

    Reviews

    Related information

    • ClinVar
      Related medical variations
    • OMIM
      Related records in OMIM
    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed
    • PubMed (OMIM)
      Related literature resources in PubMed

    Recent activity